Novel ICBs such as anti-TIM-3, anti-TIGIT, or anti-LAG-3 were also shown to restore the function of tumor-infiltrating T cells in vitro [21], and they are now under the early stage of clinical trials. Here, LAG3 is linked to neoplasm.